Evaluation of Serum IL-39 Levels in Patients with Polycystic Ovary Syndrome
Journal of Clinical Medicine · 20.05.2026 · 15 (10) · 3958
DOI: 10.3390/jcm15103958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.05.2026. Verfasst von Mehmet Kagitci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recep Tayyip Erdoğan University, Recep Tayyip Erdoğan University Scientific Research Project, Recep Tayyip Erdogan University Development Foundation.
Abstract (Originalsprache)
Background/Objectives: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with chronic low-grade inflammation. Interleukin-39 (IL-39), a newly identified cytokine, has been implicated in immune regulation; however, its role in PCOS remains unclear. This study aimed to evaluate serum IL-39 levels in patients with PCOS and its potential as an adjunctive inflammatory biomarker candidate.
Methods
This case–control study included 44 patients with PCOS diagnosed according to the Rotterdam criteria and 44 age-matched in the control group. Serum IL-39 levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory parameters were recorded. Group comparisons were performed using appropriate parametric and non-parametric tests. Correlation analysis was conducted using Spearman’s coefficient. Multivariable logistic regression analysis was performed to identify independent predictors of PCOS. Receiver operating characteristic (ROC) analysis was used to assess discriminative performance.
Results
Serum IL-39 levels were significantly higher in the PCOS group compared to control group (p < 0.001). No significant correlations were observed between IL-39 and other clinical or laboratory parameters. In multivariable analysis, IL-39 was independently associated with PCOS. ROC analysis showed that IL-39 had moderate discriminative ability (AUC = 0.74), with 68% sensitivity and 70% specificity. The combined model including IL-39, body mass index (BMI), luteinizing hormone (LH), and age demonstrated improved performance (AUC = 0.78), with higher sensitivity (86%) and negative predictive value (81%).
Conclusions
IL-39 levels are elevated in PCOS and may represent a potential adjunctive inflammatory biomarker candidate. Its diagnostic performance improves when combined with other clinical parameters, supporting a multivariable approach in PCOS evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey.
- Department of Medical and Clinical Microbiology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey.
- Department of Biostatistics and Medical Informatics, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey.
ORCID-Profile: Mehmet Kivrak, Sally Al Deseet
Förderung
- Recep Tayyip Erdoğan University
- Recep Tayyip Erdoğan University Scientific Research Project
- Recep Tayyip Erdogan University Development Foundation
Zitieren
APA
Kagitci, M., Bahceci, I., Kivrak, M., Deseet, S. A., & Senturk, S. (2026). Evaluation of Serum IL-39 Levels in Patients with Polycystic Ovary Syndrome. Journal of Clinical Medicine, 15(10), 3958. https://doi.org/10.3390/jcm15103958
Vancouver
Kagitci M, Bahceci I, Kivrak M, Deseet SA, Senturk S. Evaluation of Serum IL-39 Levels in Patients with Polycystic Ovary Syndrome. Journal of Clinical Medicine. 2026;15(10):3958. doi:10.3390/jcm15103958
BibTeX
@article{Kagitci2026,
author = {Kagitci, Mehmet and Bahceci, Ilkay and Kivrak, Mehmet and Deseet, Sally Al and Senturk, Senol},
title = {Evaluation of Serum IL-39 Levels in Patients with Polycystic Ovary Syndrome},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {10},
pages = {3958},
doi = {10.3390/jcm15103958}
}
EUVIMED